Data Factory
Reading the graph
Reading the graph
Gorlin family family
Aspen, CO
Healthcare-focused single family office founded and led by biotech entrepreneur Steve Gorlin
Data as of (this record's last observation) from federal regulator filings, dfx's own graph. Page built and rebuilt at most every 15 minutes.
This entity has not been resolved onto another DFX graph by a shared identifier. A name match elsewhere would be a candidate, never an identity, and none is recorded.
| Target | State | Kind | Asset class | Sector | Announced | Amount | Evidence |
|---|---|---|---|---|---|---|---|
| CoRegen, Inc. | n/a | direct equity | biotech | cell-based cancer therapy | n/a | n/a | fact |
| C-Polar Technologies, Inc. | n/a | direct equity | biotech | antimicrobial polymers / air filtration | n/a | n/a | fact |
| Senvi | n/a | direct equity | biotech | peptide therapeutics / senescence | n/a | n/a | fact |
| Oxia, Inc. | n/a | direct equity | biotech | small-molecule epigenetic therapeutics | n/a | n/a | fact |
| IntrePro | n/a | direct equity / spinout | biotech | medical device / infection control | n/a | n/a | fact |
| Hycor Biomedical | n/a | direct equity (exited) | biotech | monoclonal antibodies / diagnostics | n/a | $100M | fact |
| Theragenics Corporation | n/a | direct equity (exited) | biotech | palladium implants for prostate cancer | n/a | $1.0B | fact |
| CytRx Corporation | n/a | direct equity (exited) | biotech | cardiovascular / blood flow products | n/a | $200,000 | fact |
| Medicis Pharmaceutical Corporation | n/a | direct equity (exited) | biotech | dermatology | n/a | $2.7B | fact |
| EntreMed | n/a | direct equity (exited, as Chairman) | biotech | anti-angiogenesis technology | n/a | $1.4B | fact |
| Medivation, Inc. | n/a | direct equity (exited) | biotech | prostate cancer drugs | n/a | $14B | fact |
| MRI Interventions | n/a | direct equity | biotech | minimally invasive surgical platforms | n/a | n/a | fact |
| MiMedx | n/a | direct equity | biotech | tissue regeneration | n/a | $1.1B | fact |
| DARA BioSciences | n/a | direct equity | biotech | neuropathic pain and cancer treatment | n/a | $800,000 | fact |
| Perma-Fix Environmental Services | n/a | direct equity (exited) | environmental | nuclear waste cleanup | n/a | $100M | fact |
| Pretty Good Privacy, Inc. | n/a | direct equity (exited) | technology | encryption software | n/a | $38.0M | fact |
| Judicial Correction Services | n/a | direct equity (exited) | services | private probation services | n/a | n/a | fact |
| Kabbage | n/a | direct equity (exited) | fintech | small business loans | n/a | $875M | fact |
| Person | Title | Role | Seniority | Family member | Current | Evidence |
|---|---|---|---|---|---|---|
| John Mogford | Defense Science & Technology Advisor | other | unknown | no | yes | fact |
| Elena Ulansky | Managing Partner | cio | senior | no | yes | fact |
| Steph Cence | Executive Partner | leadership | senior | no | yes | fact |
| Steve Gorlin | Principal & Founder | Family principal | senior | yes | yes | fact |
| Marc Gorlin | Entrepreneur (son of founder) | Family principal | senior | yes | yes | fact |
| John Thomas | Cfo | operations | unknown | no | yes | fact |
| Michael Mansour | Chief Science Officer | other | unknown | no | yes | fact |
| Franklyn Prendergast | Director Emeritus | board | unknown | no | yes | fact |
| Jesse Crowne | Managing Partner | leadership | senior | no | no | fact |
Also named here, with no published line of their own (reach them through the firm): John Mogford (Defense Science & Technology Advisor), Franklyn Prendergast (Director Emeritus), Michael Mansour (Chief Science Officer), Steph Cence (Executive Partner), John Thomas (CFO), Elena Ulansky (Managing Partner), Marc Gorlin (Entrepreneur (son of founder)), Steve Gorlin (Principal & Founder).
Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan